Dysregulation of miRNA expression has been associated with many cardiovascular diseases in animal models, as well as in patients. In the present review, we summarize recent findings on the role of miRNAs in cardiovascular diseases and discuss the opportunities, possibilities and challenges of using miRNAs as future therapeutic targets. Furthermore, we focus on the different approaches that can be used to deliver these newly developed miRNA therapeutics to their sites of action. Since siRNAs are structurally homologous with the miRNA therapeutics, important lessons learned from siRNA delivery strategies are discussed that might be applicable to targeted delivery of miRNA therapeutics, thereby reducing costs and potential side effects, and improving efficacy.
Skip Nav Destination
Article navigation
Review Article|
May 21 2014
Targeted delivery of miRNA therapeutics for cardiovascular diseases: opportunities and challenges
Rick F. J. Kwekkeboom;
Rick F. J. Kwekkeboom
1
*Department of Physiology, VU University Medical Center, Van der Boechorststraat 7, 1081 BT, Amsterdam, The Netherlands
Search for other works by this author on:
Zhiyong Lei;
Zhiyong Lei
1
†Experimental Cardiology Laboratory, Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, P.O. Box 85500, 3508 GA, Utrecht, The Netherlands
Search for other works by this author on:
Pieter A. Doevendans;
Pieter A. Doevendans
†Experimental Cardiology Laboratory, Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, P.O. Box 85500, 3508 GA, Utrecht, The Netherlands
‡ICIN, Netherlands Heart Institute, Catharijnesingel 52, 3511 GC Utrecht, The Netherlands
Search for other works by this author on:
René J. P. Musters;
René J. P. Musters
*Department of Physiology, VU University Medical Center, Van der Boechorststraat 7, 1081 BT, Amsterdam, The Netherlands
Search for other works by this author on:
Joost P. G. Sluijter
†Experimental Cardiology Laboratory, Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, P.O. Box 85500, 3508 GA, Utrecht, The Netherlands
‡ICIN, Netherlands Heart Institute, Catharijnesingel 52, 3511 GC Utrecht, The Netherlands
Correspondence: Dr Joost P.G. Sluijter (email [email protected]).
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
January 02 2014
Revision Received:
February 19 2014
Accepted:
March 04 2014
Online ISSN: 1470-8736
Print ISSN: 0143-5221
© The Authors Journal compilation © 2014 Biochemical Society
2014
Clin Sci (Lond) (2014) 127 (6): 351–365.
Article history
Received:
January 02 2014
Revision Received:
February 19 2014
Accepted:
March 04 2014
Citation
Rick F. J. Kwekkeboom, Zhiyong Lei, Pieter A. Doevendans, René J. P. Musters, Joost P. G. Sluijter; Targeted delivery of miRNA therapeutics for cardiovascular diseases: opportunities and challenges. Clin Sci (Lond) 1 September 2014; 127 (6): 351–365. doi: https://doi.org/10.1042/CS20140005
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() |